APA (7th ed.) Citation

D, K., NS, S., S, W., MH, K., CK, L., SS, H., . . . HJ, C. (2026). Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer. Clinical and molecular hepatology, 32(2), 721. https://doi.org/10.3350/cmh.2025.1019

Chicago Style (17th ed.) Citation

D, Kim, et al. "Molecular Determinants of Outcome to Gemcitabine, Cisplatin, and Nab-paclitaxel in Patients with Advanced Biliary Tract Cancer." Clinical and Molecular Hepatology 32, no. 2 (2026): 721. https://doi.org/10.3350/cmh.2025.1019.

MLA (9th ed.) Citation

D, Kim, et al. "Molecular Determinants of Outcome to Gemcitabine, Cisplatin, and Nab-paclitaxel in Patients with Advanced Biliary Tract Cancer." Clinical and Molecular Hepatology, vol. 32, no. 2, 2026, p. 721, https://doi.org/10.3350/cmh.2025.1019.